Semaglutide vs. Tirzepatide
Semaglutide and tirzepatide are both used for physician-supervised medical weight loss. This page compares how they work, side by side — it is educational information, not medical advice, and not a recommendation for either medication. Which one, if either, is appropriate for you is determined by a licensed provider during your evaluation.
Choose your appointment time in Vagaro — you'll be asked to sign in or create a free account (Vagaro, Google, Facebook, or Apple) to hold your slot — then complete your secure $32 consultation payment. Your appointment is held as pending until payment is received. After paying, watch your email for confirmation and next steps. Already booked? Pay your $32 fee →
At a Glance
The two medications share more similarities than differences: both are once-weekly injections, both require a clinical evaluation before prescribing, both carry a similar side-effect profile, and both share the same class-wide contraindication for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). The core difference is mechanism.
| Factor | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor mechanism | GLP-1 receptor agonist only | Dual GIP and GLP-1 receptor agonist |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Dose titration | Started low and adjusted by your provider over time | Started low and adjusted by your provider over time |
| Common side effects | Nausea, vomiting, diarrhea, constipation, decreased appetite, injection-site reactions | Nausea, vomiting, diarrhea, constipation, decreased appetite, injection-site reactions |
| Serious risk considerations | Pancreatitis, gallbladder problems, kidney problems; not recommended with personal/family MTC or MEN2 history | Pancreatitis, gallbladder problems, kidney problems; not recommended with personal/family MTC or MEN2 history |
| Brand names referenced in clinical literature | Ozempic, Wegovy | Mounjaro, Zepbound |
| Formulation TrimDoc may prescribe | Compounded or brand-name, depending on clinical appropriateness and availability | Compounded or brand-name, depending on clinical appropriateness and availability |
The Mechanism Difference
Semaglutide is a GLP-1 receptor agonist — it acts on a single hormone pathway (glucagon-like peptide-1). Tirzepatide is a dual agonist, acting on both the GLP-1 receptor and a second receptor, GIP (glucose-dependent insulinotropic polypeptide). Both hormones play a role in appetite regulation and blood sugar control. This is a mechanism description, not a claim about how much weight any individual might lose — that depends on many factors your provider will discuss with you.
Side Effects and Risk
Both medications share a similar gastrointestinal side-effect profile — nausea, vomiting, diarrhea, constipation, decreased appetite, and injection-site reactions are commonly reported with either. Serious risk considerations, including pancreatitis, gallbladder problems, and the MTC/MEN2 contraindication, apply to both. Neither medication is presented here as having a meaningfully different safety profile from the other; individual risk depends on your health history. See the full GLP-1 Side Effects guide for detail that applies to both.
How a Provider Might Approach the Choice
When both medications could reasonably apply, a provider may weigh factors such as your prior response to a GLP-1 medication (if any), tolerability of side effects, and your specific health history. This is an individualized clinical judgment, not a formula, and not something to determine on your own before your consultation.
Learn More About Each Medication
This page is a comparison overview. For the full picture on candidacy, contraindications, storage, missed doses, and stopping therapy, see the dedicated page for each medication:
Frequently Asked Questions
Is tirzepatide more effective than semaglutide?
TrimDoc does not make comparative effectiveness claims between these medications. Individual response to any GLP-1-based medication varies, and your provider can discuss what is known about each during your evaluation.
Can my provider recommend either one for me?
Your provider determines what is clinically appropriate based on your health history, prior treatment response, and evaluation — not a preference you select independently.
Is one medication safer than the other?
Both share a similar side-effect profile and the same class-wide contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN2. Neither is described here as safer — your provider reviews your individual risk factors.
Can I switch between semaglutide and tirzepatide?
Switching is a clinical decision. Talk to your provider about your response to your current medication before making any change.
Does TrimDoc decide which one I get, or do I choose?
Your provider makes the clinical determination after your evaluation. You can share your preferences and any prior experience, but the final decision is clinical, not a menu selection.
More questions? See the full Medical Weight Loss FAQ or email care@trimdoc.io.
Related Resources
Choose an appointment time in Vagaro, then sign in or create a free account to complete your booking.